Drug Trial Radar · NCT05829226
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Dec 12, 2022
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- PureTechIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
Conditions
- AML, Adult Recurrent
- MDS
Interventions
LYT-200Drug
monoclonal antibody (mAb), targeting galectin-9 protein
VenetoclaxDrug
Bcl-2 inhibitor
AzacitidineDrug
Hypomethylating agent
DecitabineDrug
Hypomethylating agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and RP2D determination]Time frame: approximately 1 year
- Incidence of Dose Limiting Toxicities [Tolerability and RP2D determination]Time frame: approximately 1 year
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of California Irvine Medical Center
Orange, California
Baptist Health South Florida-Miami Cancer Institute
Miami, Florida
Norton Healthcare-Norton Cancer Institute
Louisville, Kentucky
Mass. General Hospital-Harvard
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Rhode Island Hospital
Providence, Rhode Island
Virginia Commonwealth University Medical Center
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.